Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib versus physician's choice chemotherapy in germline BRCA-mutated metastatic breast cancer
2013-005137-20Phase 3Unknown
- Sponsor
- AstraZeneca
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of olaparib in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-005137-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005137-20.